BCR and cancer: It is intuitive that residual cancer of a +SM impacts BCR in pT2 tumors, but is this impact diminished if the cancer has already escaped the prostate, exploiting routes via the capsule, seminal vesicles, or lymph nodes (stages pT3a, pT3b, pT4)?